Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies

Overview

Journal Nutrients

Date 2025 Feb 13

PMID 39940335

Authors

Eleonora Dileo

Francesca Saba

Mirko Parasiliti-Caprino

Chiara Rosso

Elisabetta Bugianesi

Affiliations

Soon will be listed here.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a spectrum of liver disease ranging from hepatic fat accumulation to steatohepatitis (metabolic dysfunction-associated steatohepatitis, MASH), fibrosis, cirrhosis, and potentially hepatocellular carcinoma in the absence of excessive alcohol consumption. MASLD is characterized by substantial inter-individual variability in terms of severity and rate of progression, with a prevalence that is generally higher in men than in women. Steroids metabolism is characterized by sexual dimorphism and may have an impact on liver disease progression; indeed, several therapeutic strategies targeting hormone receptors are under phase 2/3 development. Despite the fact that the importance of sexual dimorphism in the setting of MASLD is well recognized, the underlying molecular mechanisms that can potentially drive the disease toward progression are not clear. The aim of this review is to delve into the crosstalk between sexual dimorphism and steroid hormone perturbation under nutritional and pharmacological intervention.

References

Sookoian S, Pirola C . Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011; 53(6):1883-94. DOI: 10.1002/hep.24283. View

Pelusi C . The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis. Front Endocrinol (Lausanne). 2022; 13:821113. PMC: 9065269. DOI: 10.3389/fendo.2022.821113. View

Ding E, Song Y, Malik V, Liu S . Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295(11):1288-99. DOI: 10.1001/jama.295.11.1288. View

Estes C, Anstee Q, Arias-Loste M, Bantel H, Bellentani S, Caballeria J . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018; 69(4):896-904. DOI: 10.1016/j.jhep.2018.05.036. View

Fabbrini E, Rady B, Koshkina A, Jeon J, Ayyar V, Gargano C . Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLD. N Engl J Med. 2024; 391(5):475-476. DOI: 10.1056/NEJMc2402341. View

Lekakis V, Papatheodoridis G . Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2023; 122:3-10. DOI: 10.1016/j.ejim.2023.11.005. View

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81(3):492-542. DOI: 10.1016/j.jhep.2024.04.031. View

Rosso C, Caviglia G, Birolo G, Armandi A, Pennisi G, Pelusi S . Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023; 21(13):3314-3321.e3. DOI: 10.1016/j.cgh.2023.04.024. View

10.

Hutchison A, Tavaglione F, Romeo S, Charlton M . Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance. J Hepatol. 2023; 79(6):1524-1541. DOI: 10.1016/j.jhep.2023.08.030. View

11.

Meda C, Barone M, Mitro N, Lolli F, Pedretti S, Caruso D . Hepatic ERα accounts for sex differences in the ability to cope with an excess of dietary lipids. Mol Metab. 2020; 32:97-108. PMC: 6957843. DOI: 10.1016/j.molmet.2019.12.009. View

12.

Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C . Liver fat accumulation is associated with circulating PCSK9. Ann Med. 2016; 48(5):384-91. DOI: 10.1080/07853890.2016.1188328. View

13.

Vitale M, Costabile G, Bergia R, Hjorth T, Campbell W, Landberg R . The effects of Mediterranean diets with low or high glycemic index on plasma glucose and insulin profiles are different in adult men and women: Data from MEDGI-Carb randomized clinical trial. Clin Nutr. 2023; 42(10):2022-2028. DOI: 10.1016/j.clnu.2023.08.016. View

14.

Anstee Q, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D . Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020; 73(3):505-515. DOI: 10.1016/j.jhep.2020.04.003. View

15.

Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina R, Romeo S . PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol. 2013; 19(41):6969-78. PMC: 3819533. DOI: 10.3748/wjg.v19.i41.6969. View

16.

Fernandez C, Chacko E, Pappachan J . Male Obesity-related Secondary Hypogonadism - Pathophysiology, Clinical Implications and Management. Eur Endocrinol. 2019; 15(2):83-90. PMC: 6785957. DOI: 10.17925/EE.2019.15.2.83. View

17.

Marino L, Jornayvaz F . Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol. 2015; 21(39):11053-76. PMC: 4607905. DOI: 10.3748/wjg.v21.i39.11053. View

18.

Lejeune M, Westerterp K, Adam T, Luscombe-Marsh N, Westerterp-Plantenga M . Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate metabolism during a high-protein diet and measured in a respiration chamber. Am J Clin Nutr. 2006; 83(1):89-94. DOI: 10.1093/ajcn/83.1.89. View

19.

OHara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B . Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep. 2020; 2(5):100142. PMC: 7397699. DOI: 10.1016/j.jhepr.2020.100142. View

20.

Coban N, Onat A, Guclu-Geyik F, Can G, Erginel-Unaltuna N . Sex- and Obesity-specific Association of Aromatase (CYP19A1) Gene Variant with Apolipoprotein B and Hypertension. Arch Med Res. 2015; 46(7):564-71. DOI: 10.1016/j.arcmed.2015.09.004. View